Innoviva (INVA) analyst forecast and price target
Analyst forecast
Consensus of 4 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Cantor Fitzgerald | Maintained | Overweight | $34.00 from $36.00 | Aug 7, 2026 |
| BTIG | Maintained | Buy | $42.00 | Jun 22, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $46.00 | Jun 1, 2026 |
| BTIG | Maintained | Buy | $42.00 | May 26, 2026 |
| BTIG | Maintained | Buy | $42.00 from $35.00 | May 7, 2026 |
| BTIG | Maintained | Buy | $35.00 | Feb 26, 2026 |
| BTIG | Initiated Coverage | Buy | $35.00 | Feb 17, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $46.00 from $45.00 | Dec 16, 2025 |
| Cantor Fitzgerald | Maintained | Overweight | $31.00 from $29.00 | Nov 6, 2025 |
| Goldman Sachs | Initiated Coverage | Sell | $17.00 | Sep 30, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $45.00 from $40.00 | Aug 11, 2025 |
| Oppenheimer | Initiated Coverage | Outperform | $35.00 | Aug 11, 2025 |
| HC Wainwright & Co. | Initiated Coverage | Buy | $40.00 | Jul 14, 2025 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | $26.00 | Jul 11, 2025 |
| Scotiabank | Initiated Coverage | Sector Outperform | $55.00 | Mar 7, 2025 |
| Cantor Fitzgerald | Maintained | Overweight | — | Aug 1, 2024 |
| Cantor Fitzgerald | Maintained | Overweight | — | Jul 30, 2024 |
| Cantor Fitzgerald | Maintained | Overweight | — | Jun 20, 2024 |
| Cantor Fitzgerald | Initiated Coverage | Overweight | — | Jun 18, 2024 |
| EF Hutton | Maintained | Buy | $22.50 | May 10, 2023 |
Frequently asked questions
What is the price target for INVA stock?
The average 12-month analyst price target for Innoviva (INVA) is $40.67, with a high estimate of $46.00 and a low of $34.00, across 3 analysts.
Is INVA a buy, sell, or hold?
Analysts covering Innoviva currently average a Buy rating: 3 buy, 0 hold and 1 sell, from 4 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for INVA?
The average price target of $40.67 implies 95.65% upside from the last price of $20.79.
What is the latest analyst rating on INVA?
On Aug 7, 2026, Cantor Fitzgerald maintained Innoviva at Overweight with a price target of $34.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.